Literature DB >> 26531674

Effects of lentivirus-mediated shRNA targeting integrin-linked kinase on oral squamous cell carcinoma in vitro and in vivo.

Lin Que1, Dan Zhao2, Xiu-Fa Tang3, Ji-Yuan Liu3, Xiang-Yu Zhang1, Yu-Hua Zhan1, Lei Zhang1.   

Abstract

Integrin-linked kinase (ILK), a highly conserved intracellular protein of serine/threonine protein kinase activities, which is associated with the integrin and growth factor receptor signaling pathway, is involved in the regulation of cell proliferation, apoptosis, differentiation, migration and epithelial-mesenchymal transition (EMT). Findings of a previous study showed that ILK overexpression was strongly correlated with a more aggressive tumor phenotype, recurrence and poor survival for oral squamous cell carcinoma (OSCC) patients, as well as some EMT markers. In order to investigate the underlying mechanisms involved, a lentivirus-mediated short hairpin RNA (shRNA) was employed to downregulate ILK. The results showed that the knockdown of ILK inhibited cell growth, adhesion and invasion ability in vitro, and OSCC cells deficient of ILK were blocked in the S phase and underwent apoptosis. Additionally, ILK shRNA inhibited EMT by impairing the expression of Snail, Slug and Twist2 and enhacning E-cadherin expression. ILK shRNA suppressed the phosphorylation of downstream signaling targets Akt and GSk-3β. In addition, the knockdown of ILK inhibited tumor growth, invasion and metastasis of xenograft tumors in vivo. These results suggested that ILK is a promising therapeutic target for the treatment of OSCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26531674     DOI: 10.3892/or.2015.4374

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  New Perspectives on the Role of Integrin-Linked Kinase (ILK) Signaling in Cancer Metastasis.

Authors:  Paul C McDonald; Shoukat Dedhar
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

2.  Genome wide profiling in oral squamous cell carcinoma identifies a four genetic marker signature of prognostic significance.

Authors:  Vui King Vincent-Chong; Iman Salahshourifar; Kar Mun Woo; Arif Anwar; Rozaimi Razali; Ranganath Gudimella; Zainal Ariff Abdul Rahman; Siti Mazlipah Ismail; Thomas George Kallarakkal; Anand Ramanathan; Wan Mahadzir Wan Mustafa; Mannil Thomas Abraham; Keng Kiong Tay; Rosnah Binti Zain
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

3.  Emodin Inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer Cells via ILK/GSK-3β/Slug Signaling Pathway.

Authors:  Jingjing Lu; Ying Xu; Xuan Wei; Zhe Zhao; Jing Xue; Peishu Liu
Journal:  Biomed Res Int       Date:  2016-12-20       Impact factor: 3.411

4.  Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c.

Authors:  Ming-Yu Lien; An-Chen Chang; Hsiao-Chi Tsai; Ming-Hsui Tsai; Chun-Hung Hua; Shih-Ping Cheng; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

5.  MicroRNA-542-3p inhibits oral squamous cell carcinoma progression by inhibiting ILK/TGF-β1/Smad2/3 signaling.

Authors:  Bin Qiao; Jing-Hua Cai; Alfred King-Yin Lam; Bao-Xia He
Journal:  Oncotarget       Date:  2017-08-07

6.  Emodin suppresses proliferation, migration and invasion in ovarian cancer cells by down regulating ILK in vitro and in vivo.

Authors:  Jingjing Lu; Ying Xu; Zhe Zhao; Xiaoning Ke; Xuan Wei; Jia Kang; Xuan Zong; Hongluan Mao; Peishu Liu
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.345

7.  Integrin-Linked Kinase Is Involved In the Proliferation and Invasion of Esophageal Squamous Cell Carcinoma.

Authors:  Zhonghua Ning; Xiaozhong Zhu; Youqin Jiang; Aidi Gao; Shitao Zou; Chao Gu; Chao He; Yihong Chen; Wei-Qun Ding; Jundong Zhou
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

8.  Emodin Reverses the Epithelial-Mesenchymal Transition of Human Endometrial Stromal Cells by Inhibiting ILK/GSK-3β Pathway.

Authors:  Qiaomei Zheng; Jinhua Wang; Wenwen Li; Xiaoyun Chen; Shaozhan Chen; Lihong Chen
Journal:  Drug Des Devel Ther       Date:  2020-09-10       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.